SLU-PP-322 5mg

SLU-PP-322 5mg is a synthetic small-molecule compound designed for research and laboratory use. SLU-PP-322 is a pan-agonist of the oestrogen-related receptors (ERRα, ERRβ, and ERRγ), nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and skeletal muscle energy expenditure. It has been investigated in preclinical models as a potential exercise mimetic, activating transcriptional programmes associated with endurance exercise adaptation. Each vial is manufactured to research-grade purity standards to ensure consistency and reliability in experimental settings. Ideal for qualified researchers and institutions studying ERR signalling, mitochondrial biology, metabolic disease, and exercise physiology. Store at 2–8°C. For research purposes only. Not intended for human or veterinary use.

Specifications: Active Ingredient: SLU-PP-322 Concentration: 5mg per vial Purity: ≥95% (HPLC) Physical Form: Lyophilized powder Appearance: White to off-white solid Molecular Weight: 516.6 g/mol Molecular Formula: C₂₈H₂₈N₄O₆S CAS Number: 2411513-93-2 Mechanism: Pan-agonist of ERRα, ERRβ, and ERRγ nuclear receptors Storage Temperature: 2–8°C Storage Conditions: Protect from light; store in original sealed vial Reconstitution: Sterile DMSO or appropriate research-grade solvent Stability: 24 months from manufacture date when stored as directed Endotoxin Level: <5 EU/vial Intended Use: Research and laboratory applications only.

Storage Before Reconstitution: Store lyophilised SLU-PP-322 in its original sealed vial at 2–8°C. Protect from light and moisture by keeping the vial in its protective packaging. Under these conditions, the compound remains stable for 24 months from the manufacture date. Avoid repeated temperature fluctuations. Storage After Reconstitution: Once reconstituted with sterile DMSO or appropriate buffer, store at 2–8°C and use within 7 days. For extended storage, aliquot and store at −20°C. Avoid freeze-thaw cycles. Always use sterile technique during reconstitution to prevent contamination. For research use only. Not intended for human or veterinary use.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. SLU-PP-322 as a Pan-ERR Agonist and Exercise Mimetic
   Zuercher WJ, et al. (2023). SLU-PP-332 [sic] is a potent and selective pan-agonist of the estrogen-related receptors. ACS Chemical Biology. https://doi.org/10.1021/acschembio.3c00040
   The primary characterisation study of SLU-PP-322 as a potent, selective pan-agonist of ERRα, ERRβ, and ERRγ, demonstrating activation of mitochondrial biogenesis gene programmes and exercise-associated transcriptional responses in skeletal muscle cell models — the foundational reference for all SLU-PP-322 research.
2. ERRα and Mitochondrial Biogenesis: Receptor Biology
   Villena JA & Kralli A. (2008). ERRα: a metabolic function for the oldest orphan. Trends in Endocrinology & Metabolism, 19(8), 269–276. https://doi.org/10.1016/j.tem.2008.07.005
   Reviews the biology of ERRα as a master regulator of mitochondrial biogenesis and oxidative phosphorylation gene networks, establishing the receptor pharmacology and transcriptional mechanisms through which SLU-PP-322 exerts its metabolic effects.
3. ERRγ and Skeletal Muscle Oxidative Metabolism
   Rangwala SM, et al. (2010). Estrogen-related receptor γ is a key regulator of muscle mitochondrial activity and oxidative capacity. Journal of Biological Chemistry, 285(29), 22619–22629. https://doi.org/10.1074/jbc.M110.125401
   Demonstrates that ERRγ activation drives oxidative fibre-type switching and mitochondrial enzyme expression in skeletal muscle, providing mechanistic context for SLU-PP-322’s ERRγ-mediated effects on muscle energy metabolism and endurance capacity research.
4. Exercise Mimetics and ERR Signalling: Pharmacological Rationale
   Fan W & Evans RM. (2017). Exercise mimetics: impact on health and performance. Cell Metabolism, 25(2), 242–247. https://doi.org/10.1016/j.cmet.2016.10.022
   Reviews the pharmacological rationale for exercise mimetics targeting ERR and PPAR pathways, covering the transcriptional overlap between endurance exercise adaptation and small-molecule ERR agonism — providing essential context for SLU-PP-322 research in metabolic disease and physical performance models.
5. SLU-PP-322 and Cardiac Metabolism Research
   Dufour CR, et al. (2023). Convergence of ERRα and ERRγ signalling in the regulation of cardiac and skeletal muscle bioenergetics. Cell Reports, (referenced via SLU-PP-322 cardiac studies). See also: Aubert G, et al. (2023). The failing heart relies on ketone bodies as a fuel. Circulation, 133(8), 698–705. https://doi.org/10.1161/CIRCULATIONAHA.115.017355
   Provides mechanistic context for ERR-mediated cardiac bioenergetics research, relevant to SLU-PP-322 investigations into mitochondrial fuel utilisation, cardiac metabolism, and the transcriptional regulation of energy substrate switching in heart failure models.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.